AstraZeneca likely to run new trial on COVID-19 vaccine – Bloomberg
|AstraZeneca's Chief Executive Pascal Soriot announced on Thursday that they could run a new global trial to evaluate the efficacy of the coronavirus vaccine candidate, Bloomberg News reported on Thursday.
According to the report, the company is likely to start a new trial to assess the performance of the lower dosage separate from the trial that is already underway in the US.
Market reaction
The lack of activity in the financial markets makes it difficult to see if this headline had an impact on market sentiment. As of writing, the US Dollar Index was posting small daily gains at 92.05.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.